Entity

Time filter

Source Type

Cambridge, MA, United States

Patent
ARIAD Pharmaceuticals Inc. and Merck | Date: 2014-04-30

The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an v62 3 integrin antagonist, wherein the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2013-03-15

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2015-04-20

The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2013-03-15

The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2013-03-15

The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

Discover hidden collaborations